Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: A single-centre experience

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1589-1593

  Gillessen, S ^a,b   Powles, T ^a   Lim, L ^a   Wilson, P ^a   Shamash, J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Baby BOP; Germ cell tumour; Low dose induction chemotherapy; Poor prognosis

Indexed keywords

BLEOMYCIN; CISPLATIN; DACTINOMYCIN; ETOPOSIDE; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; THORAX PAIN; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING;

EID: 77955237964     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq019     Document Type: Article

References (15)

1. IGCCCG. A prognostic factor based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
2. Shamash J, Powles T, Ansell W et al. GAMEC-a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. Br J Cancer 2007; 97: 308-314.
3. Bower M, Newlands ES, Holden L et al. Treatment of men with metastatic nonseminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 1997; 8(5): 477-483.
4. Shamash J, Oliver RT, Ong J et al. Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy. Ann Oncol 1999; 10(6): 685-692.
5. Christian JA, Huddart RA, Norman A et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003; 21(5): 871-877.
6. de Wit R, Stoter G, Sleijfer DT et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular nonseminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1995; 71(6): 1311-1314.
7. Roth BJ, Greist A, Kubilis PS et al. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol 1988; 6(8): 1239-1247.
8. Lewis CR, Fossa SD, Mead G et al. BOP/VIP-a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 1991; 2: 203-211.
9. Kaye S, Mead G, Fossa SD et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment of metastatic nonseminomatous germ cell tumour. J Clin Oncol 1998; 16: 692-701.
10. Christian JA, Huddart RA, Norman A et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003; 21: 871-877.
11. Anthoney DA, McKean MJ, Roberts JT et al. Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours. Br J Cancer 2004; 90: 601-606.
12. Motzer RJ, Nichols CJ, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25: 247-256.
13. Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21: 4083-4091.
14. Hartmann JT, Gauler T, Metzner B et al. Phase I/II study of sequential doseintensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol 2007; 25: 5742-5747.
15. Germa-Lluch JR, Garcia del Muro X, Tabernero JM et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol 1999; 10: 289-293.